- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04231097
MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms
Mindfulness-Based Cognitive Therapy Delivered Via Group Videoconferencing for Acute Coronary Syndrome Patients With Depressive Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current study will employ an open pilot trial to determine the initial feasibility and acceptability of a targeted, virtual MBCT intervention for ACS patients. The investigators plan to enroll approximately N=20 patients (2 cohorts of 10 participants/per cohort, accounting for 20% anticipated lost to follow-up). The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
Participants will be recruited through the the hospital's clinical data registry, advertisements (e.g., flyers, brochures) placed throughout the hospital, direct provider referrals, and from inpatient cardiac units. Patients who express interest in the study will be asked complete an eligibility screening. Eligible patients agreeable with study participation will then complete a written consent with study staff prior to enrollment.
Participants will be enrolled in one of two MBCT intervention cohorts and expected to participate in 8-weekly, 1.5-hour virtual sessions, in conjunction with approximately 30 minutes of at-home daily practice. A licensed mental health provider (e.g., LICSW, PhD) trained in the MBCT protocol will deliver the intervention. The MBCT intervention will be delivered Zoom, a secure, HIPPA-compliant video-conferencing software.
Study assessments will include a battery of self-report surveys administered at baseline, post-intervention, and 3-month follow-up; session satisfaction surveys administered after each intervention session; post-intervention individual exit interviews (conducted via telephone or videoconference); blood spot samples self-collected by participants at baseline, post-intervention, and 3-month follow-up (submitted to the research team via paper mail); and home practice logs submitted between each intervention session. Primary outcomes for the intervention are feasibility and acceptability. Data collected from the study will be used to assist in the development of future RCTs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Mongan Institute: Health Policy Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Lifetime ACS per medical record and/or patient confirmation
- Current elevated depression symptoms (PHQ-9>5)
- Age 35-85 years
- Access to high-speed internet
Exclusion Criteria:
- Active suicidal ideation or past-year psychiatric hospitalization (per patient report and/or medical record review)
- Non-English-speaking
- Cognitive impairments preventing informed consent per medical record review and/or cognitive Screen < 4
- Patient deemed unable to complete the study protocol or has a condition that would likely interfere with the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Virtual MBCT
Two cohorts of MBCT participants with approximately 10 participants per cohort.
|
The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
Participants involved in the intervention will be asked to complete a brief survey following each session.
Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples.
Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Feasibility: Percent of Participants Who Consent to Screening
Time Frame: 6 months
|
Feasibility outcomes for recruitment will include: >70% of patients reached consent to screening
|
6 months
|
|
Recruitment Feasibility: Percent of Participants Meeting Screening Criteria
Time Frame: 6 months
|
Feasibility outcomes for recruitment will include: >70% meet screening criteria
|
6 months
|
|
Recruitment Feasibility: Percent of Eligible Patients Who Consent
Time Frame: 6 Months
|
Feasibility outcomes for recruitment will include: >70% of eligible consent to the study
|
6 Months
|
|
MBCT Feasibility: Percent of Participants Adherent to the MBCT Intervention
Time Frame: 6 Months
|
MBCT feasibility will be measured by: >75% session attendance (i.e., percent who attend at least 6/8 intervention sessions)
|
6 Months
|
|
MBCT Feasibility: Percent of Participants Retained at Post-Intervention
Time Frame: 3 Months
|
MBCT feasibility will be measured by: >75% post-intervention assessments completed
|
3 Months
|
|
Videoconferencing Feasibility: Percent of Connections Dropped During Sessions
Time Frame: 6 Months
|
Videoconferencing feasibility will be assessed by: < 20% of connections dropped during session
|
6 Months
|
|
Blood Spot Feasibility: Percent of Participants Submitting Blood Spot Samples at Baseline
Time Frame: 6 months
|
Blood spot feasibility will be assessed by: >75% of participants submitting samples at baseline
|
6 months
|
|
Blood Spot Feasibility: Percent of Participants Submitting Blood Spot Sample at Post-Intervention
Time Frame: 6 Month
|
Blood spot feasibility will be assessed by: >75% of participants submitting samples at post-intervention
|
6 Month
|
|
Blood Spot Feasibility: Percent of Participants Submitting Blood Spot Samples at Follow-up
Time Frame: 6 Months
|
Blood spot feasibility will be assessed by: >60% of participants submitting samples at follow-up
|
6 Months
|
|
Blood Spot Feasibility: Percent of Adequate Blood Spot Samples Submitted
Time Frame: 6 Months
|
Blood spot feasibility will be assessed by: 80% of samples of adequate quality for processing.
|
6 Months
|
|
MBCT Acceptability: Helpfulness for Mood
Time Frame: 6 months
|
Ratings of how helpful the MBCT sessions were for improving mood (1 = not at all helpful to 10 = very helpful), with acceptability defined as Mean >= 7.5
|
6 months
|
|
MBCT Acceptability: Usefulness of Session Components
Time Frame: 6 months
|
The average usefulness ratings for session components on a scale of 1 = not at all useful to 10 = very useful, with mean >= 7.5 being considered acceptable
|
6 months
|
|
Videoconferencing Acceptability: Ratings of Videoconferencing Ease of Use
Time Frame: 6 Months
|
Videoconferencing acceptability will be assessed in terms of ease of use (1= very much, 10 = not at all; M >= 7.5)
|
6 Months
|
|
Videoconferencing Acceptability: Ratings of Videoconferencing Quality Surveys)
Time Frame: 6 Months
|
Videoconferencing acceptability will be assessed in terms of video quality of mindfulness videoconference sessions (1= Very Poor to 10 = Very Good, M>7.5)
|
6 Months
|
|
Videoconferencing Acceptability: Ratings of Videoconferencing Satisfaction
Time Frame: 6 Months
|
Videoconferencing acceptability will be assessed in overall satisfaction of use (1 = not at all satisfied to 10 = very satisfied, M > 7.5)
|
6 Months
|
|
Blood Spot Acceptability: Ease of Blood Spot Collection
Time Frame: Average rating for ease of data submission from blood spot collection through out all groups
|
Blood spot acceptability will be assessed by ratings of ease of blood spot collection (1 = not at all, 10 = very easy; M>7.5)
|
Average rating for ease of data submission from blood spot collection through out all groups
|
|
Blood Spot Acceptability: Discomfort of Blood Spot Collection
Time Frame: 6 Months
|
Blood spot acceptability will be assessed by ratings of level of pain during blood spot collection, (1=Very much pain, 10=Very little pain; M>=7.5).
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Health Questionnaire (PHQ-9)
Time Frame: 6 months
|
This is a 9-item scale that measures depression.
The scoring scale ranges from 0, not at all, to 3, nearly every day.
The scoring values range from 0-18, where high values represent higher levels of depression and lower values represent lower levels of depression.
Changes of >= 3 points from before to after the intervention represent clinically meaningful change.
The outcome is the % of participants who report clinically meaningful change
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christina Luberto, PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020P000045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
Bekelu Teka WorkuJimma UniversityNot yet recruitingPrenatal Depression | Mental Health Related Quality of Life | Maternal Postpartum Depression | Paternal Postpartum DepressionEthiopia
Clinical Trials on MBCT intervention for ACS patients
-
Russian Academy of Medical SciencesUnknownAcute Coronary SyndromeRussian Federation
-
Lakehead UniversityOntario Neurotrauma FoundationCompletedDepression | Traumatic Brain InjuryCanada
-
Kuopio University HospitalTurku University Hospital; UKK InstituteRecruitingCoronary Artery Disease | Aortic Valve Stenosis | Mitral Valve InsufficiencyFinland
-
Clemson UniversityPrisma Health-UpstateCompletedMajor Depressive DisorderUnited States
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
St. John's Research InstituteNational Heart and Lung InstituteCompletedAcute Coronary SyndromeIndia
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEvaluation of the Effectiveness of an Educational Intervention in Splenectomized Patients (SPLE-VAC)Asplenia | Splenectomy | Splenectomy; Status | Splenectomized PatientsItaly
-
Istanbul University - CerrahpasaRecruitingAcceptance and Commitment TherapyTurkey
-
AstraZenecaCompletedTreatment of Acute Coronary Syndrome (ACS).Belgium